The epidemiology and impact of disorders of gut-brain interaction in Canada: Results from the Rome Foundation Global Epidemiologic Study.
Canada
disorders of gut-brain interaction
functional dyspepsia
irritable bowel syndrome
prevalence
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
10
03
2023
received:
30
01
2023
accepted:
15
03
2023
medline:
4
5
2023
pubmed:
30
3
2023
entrez:
29
3
2023
Statut:
ppublish
Résumé
Using data from the Rome Foundation Global Epidemiology Study examining prevalence of disorders of gut-brain interaction (DGBI) in 33 countries, this study explored the prevalence of all 22 disorders in Canada. It examined differences related to geography and sociodemographic factors, health impact and compared these findings to other countries. The Rome Foundation survey was conducted through the Internet, targeting 2000 Canadian participants. The survey used the validated ROME IV diagnostic questionnaire to identify the 22 DGBI and an in-depth supplemental questionnaire that included quality assurance techniques. There were 2029 respondents with a mean age of 48 years and 50% females. Diagnostic criteria for at least one of the 22 DGBI were met by 41.3%, similar to other countries. Functional constipation, functional diarrhea, and unspecified functional bowel disorders were most common. Irritable bowel syndrome prevalence was 4.2% using Rome IV and 10.1% using ROME III criteria. DGBI were associated with poorer quality of life and increased psychological symptom scores. Prevalence of DGBI ranged from 48% in Quebec to 36% in British Columbia. Prescription pain medication was reported by 17% with DGBI compared to 9% without DGBI and correlated negatively with mental health and physical well-being. Quebecers and francophones were in limited number but reported higher DGBI prevalence and symptom severity compared to others. A large proportion of Canadians suffer from DGBI which seriously impact their well-being. Findings highlight the need for further research and education, including understanding whether significant regional and cultural differences contribute to DGBI.
Sections du résumé
BACKGROUND
Using data from the Rome Foundation Global Epidemiology Study examining prevalence of disorders of gut-brain interaction (DGBI) in 33 countries, this study explored the prevalence of all 22 disorders in Canada. It examined differences related to geography and sociodemographic factors, health impact and compared these findings to other countries.
METHODS
The Rome Foundation survey was conducted through the Internet, targeting 2000 Canadian participants. The survey used the validated ROME IV diagnostic questionnaire to identify the 22 DGBI and an in-depth supplemental questionnaire that included quality assurance techniques.
KEY RESULTS
There were 2029 respondents with a mean age of 48 years and 50% females. Diagnostic criteria for at least one of the 22 DGBI were met by 41.3%, similar to other countries. Functional constipation, functional diarrhea, and unspecified functional bowel disorders were most common. Irritable bowel syndrome prevalence was 4.2% using Rome IV and 10.1% using ROME III criteria. DGBI were associated with poorer quality of life and increased psychological symptom scores. Prevalence of DGBI ranged from 48% in Quebec to 36% in British Columbia. Prescription pain medication was reported by 17% with DGBI compared to 9% without DGBI and correlated negatively with mental health and physical well-being. Quebecers and francophones were in limited number but reported higher DGBI prevalence and symptom severity compared to others.
CONCLUSIONS & INFERENCES
A large proportion of Canadians suffer from DGBI which seriously impact their well-being. Findings highlight the need for further research and education, including understanding whether significant regional and cultural differences contribute to DGBI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14585Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2021;160:99-114.e3.
Tack J, Stanghellini V, Mearin F, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019;19:69.
Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56:844-856.
Leong SA, Barghout V, Birnbaum HG, et al. The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med. 2003;163:929-935.
Chuah KH, Cheong SY, Lim SZ, Mahadeva S. Functional dyspepsia leads to more healthcare utilization in secondary care compared with other functional gastrointestinal disorders. J Dig Dis. 2022;23:111-117.
Suleiman S, Sonnenberg A. Cost-effectiveness of endoscopy in irritable bowel syndrome. Arch Intern Med. 2001;161:369-375.
Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. Frontline Gastroenterol. 2014;5:266-271.
Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 2002;47:225-235.
Fedorak RN, Vanner SJ, Paterson WG, Bridges RJ. Canadian Digestive Health Foundation public impact series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol. 2012;26:252-256.
Statistics Canada. Immigration and ethnocultural diversity statistics. Accessed September 29, 2022. https://www.statcan.gc.ca/en/subjects-start/immigration_and_ethnocultural_diversity.
Sperber AD, Freud T, Abu-Freha N, et al. Epidemiology of disorders of gut-brain interaction in Israel: results from the Rome Foundation global epidemiology study. Neurogastroenterol Motil. 2022;34:e14323.
Tornkvist NT, Aziz I, Whitehead WE, et al. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. United Eur Gastroenterol J. 2021;9:1178-1188.
Palsson OS, Whitehead WE, Van TMAL, et al. Rome IV diagnostic questionnaires and tables for investigators and clinicians. Gastroenterology. 2016;150:1481-1491.
Kroenke K, Spitzer RL, Williams JBW, Löwe B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics. 2009;50:613-621.
Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther. 2010;32:811-820.
Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009;18:873-880.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11:395-402.
Statistics Canada. Census Profile. 2021 Census of Population. Statistics Canada Catalogue number 98-316-X2021001. Ottawa. 2023. Released February 8, 2023.
Sperber AD, Freud T, Aziz I, et al. Greater overlap of Rome IV disorders of gut-brain interactions leads to increased disease severity and poorer quality of life. Clin Gastroenterol Hepatol. 2022;20:e945-e956.
Ju C, Wei L, Man KKC, et al. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. Lancet Public Heal. 2022;7:e335-e346.
Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158:1262-1273.e3.
Goodoory VC, Houghton LA, Yiannakou Y, Black CJ, Ford AC. Natural history and disease impact of Rome IV vs Rome III irritable bowel syndrome: a longitudinal follow-up study. Clin Gastroenterol Hepatol. 2022;20:569-577.e3.
Luo Y, Camey SA, Bangdiwala SI, Palsson OS, Sperber AD, Keefer LA. Global patterns of prescription pain medication usage in disorders of gut-brain interactions. Neurogastroenterol Motil. 2023;35:e14457.
Humphreys K, Shover CL, Andrews CM, et al. Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-lancet commission. Lancet. 2022;399:555-604.
Carrière G, Garner R, Sanmartin C. Significant factors associated with problematic use of opioid pain relief medications among the household population, Canada, 2018. Heal Reports. 2021;32:13-26.
Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22:424-e96.
Farmer AD, Gallagher J, Bruckner-Holt C, Aziz Q. Narcotic bowel syndrome. Lancet Gastroenterol Hepatol. 2017;2:361-368.
Tremblay M, Vézina H, Desjardins B, Houde L. Distant kinship and founder effects in the quebec population. In: Bengtsson T, Mineau GP, eds. Kinship and Demographic Behavior in the Past. Vol 7. International Studies in Population; 2008.
Talley NJ, Ford AC. Functional dyspepsia. N Engl J Med. 2015;373:1853-1863.
Van Den HK, Bercik P, Simren M, Tack J, Vanner S. Mechanisms underlying food-triggered symptoms in disorders of gut-brain interactions. Am J Gastroenterol. 2022;117:937-946.
Batal M, Makvandi E, Imbeault P, et al. Comparison of dietary intake between Francophones and Anglophones in Canada: data from CCHS 2.2. Can J Public Health. 2013;104:104-S38.
Trudeau K, Rousseau MC, Csizmadi I, Parent MÉ. Dietary patterns among French-speaking men residing in Montreal, Canada. Prev Med Rep. 2019;13:205-213.